Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, ...
REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with ...